Models Exposed

Published Sep 17, 2012
Princeton, NJ, USA – As consumers, we are becoming experts at scrutinizing the reviews our peers write about products we are thinking of buying. We ask ourselves if the comments written in the review truly fit the product, are the comments promotional or too negative, or simply unrelated to the product itself. Health care decision makers are starting to do this with modeling studies. They are asking themselves, “Where is this information coming from? Are the results realistic? Are they relevant to my decision?” Dr. Jaime Caro, co-author on the paper, “Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-7,” states, “For decision makers to trust the results of models, these must be shown to be valid in the sense of being sufficiently accurate and relevant. This subgroup of the ISPOR-SMDM Modeling Task Force detailed the steps required to ensure the validity of models and grappled with the difficult balance between transparency and protection of intellectual property, proposing a compromise that should provide for full scientific review of models.”  This paper provides guidance for health care researchers to ensure that their models are both transparent and valid. This paper is one of the seven papers in the series on modeling study best practices and is jointly published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and Medical Decision Making, the official journal of the Society for Medical Decision Making (SMDM).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×